Focus: B. Braun is a German-headquartered medical device and pharmaceutical company specializing in infusion therapy, pain management, and critical care solutions across cardiovascular, infectious disease, and metabolic disease areas. The company operates as an integrated healthcare provider with a diversified portfolio spanning devices, generics, and specialty therapeutics.
Profile data last refreshed 4h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow B. Braun to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Core revenue driver but approaching loss of exclusivity with no designated patent protection; represents commodity-level competition risk.
Help build intelligence for B. Braun
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from B. Braun's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Critical anticoagulant but generic commodity with multiple competitors; lifecycle stage indicates imminent patent cliff.
Specialized renal therapy formulation but LOE approaching limits long-term revenue stability.
Post-LOE generic with entrenched market position; stable but mature revenue source aligned with company pain management specialty.
Infectious disease franchise but nearing LOE; competes in commoditized antibiotic market.
143 discontinued, 91 duplicate formulations not shown
+32 more products
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moSource: USCIS H-1B Employer Data Hub
Two active product shortages (Lidocaine Hydrochloride Injection, Dextrose 10% Injection) on supply status but marked 'Available'—operational risk mitigated; no WARN Act filings or FDA warnings visible, but patent cliff exposure and zero job openings are primary career concerns.
+1 more